Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thyroid hormone receptor interactor 11 (TRIP11) is a protein predominantly associated with the Golgi apparatus, where it functions as a membrane tether required for vesicle tethering and maintains the structure and function of the Golgi complex[1][2][5][6][7]. It is crucial for intracellular protein transport—particularly in the trafficking between the endoplasmic reticulum (ER) and the Golgi—and also serves as a coactivator for thyroid hormone receptors, enhancing thyroid hormone receptor-mediated transcription in the presence of ligands like triiodothyronine[2][7]. Mutations in TRIP11 lead to severe skeletal disorders such as achondrogenesis type 1A and odontochondrodysplasia, reflecting its especially important function in chondrocytes during cartilage and bone development[1][2][4][5]. TRIP11 is not a druggable receptor, enzyme, transporter, or typical therapeutic target, and no interacting drugs or clinical biomarkers are currently known[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thyroid hormone receptor interactor 11 (TRIP11).